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evaluation and allows clearly define the contours of the 
tumor for planning brachytherapy.  
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Purpose/Objective: Uterine cervical carcinoma is still 
remaining one of the main mortality reasons for female 
population in the developing world. Inspite of widely 
accessible screening and diagnostic procedures in the vast 
majority of cases in our country cervical cancer is revealed in 
locally advanced stages with metastasis in pelvic and 
paraaortal lymph nodes in up to 34% of patients. Concurrent 
chemoradiotherapy is the treatment of choice for cervical 
cancer today but the presence of positive lymph nodes 
require escalation of EBRT dose to these targets. The aim of 
this research was analysis of treatment results of 62 node 
positive cervical cancer patients. 
Materials and Methods: We used the method of integrated 
boost by volumetric arc therapy (VMAT) to increase the EBRT 
dose in target while keeping relatively low doses at the 
organs at risk (bowel, rectum, bladder, femoral heads, pelvic 
bones). Planning was done in automatic regimen and the dose 
distribution was better (more conformal) if two dynamic arcs 
with 15 MV photon beams were used. Number of fractions 
were 25. Fraction dose prescribed to the pelvis (primary 
tumor and regional zone) was 2.0 Gy while to the metastatic 
lymph nodes – 2.3 Gy at the same fraction what makes totally 
50 and 59 Gy respectively (EQD2 by α/β = 10). From the first 
day of treatment patients received concurrently weekly 
cisplatin in dose 40 mg/m2 (max. 70 mg), 5 infusions. After 46 
Gy of EBRT we started HDR brachytherapy which was 
consisted of two weekly 9.0 Gy fractions to HRCTV. 
Results: We analysed close results of the treatment which 
were assessed one month after the course completed. 
Complete regression, partial regression and stabilisation of 
the tumor developed in 83,9% (n=52), 11,3% (n=7), and 4,8% 
(n=3) cases respectively. Early hematological toxicity, 
enteritis, rectitis and cystitis of II – III stages observed in 
42,3%, 15,4%, 11,2% and in 4,3% cases accordingly. 
Conclusions: VMAT EBRT with integrated boost, HDR 
brachytherapy and concurrent cisplatin appears to be safe 
and effective treatment modality for pelvic lymph node 
metastatic uterine cervical carcinoma providing high rate 
local tumor control and acceptable early toxicity. But to do 
final conclusions we need longer follow up period. 
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Purpose/Objective: Treatment of locally advanced cervical 
cancer combines chemotherapy, EBRT and intracavity 
brachytherapy. Differing dose and fractionation schedules 
exist for the use of intracavity brachytherapy in cervical 
carcinoma. Following the switch from MDR to HDR in 2007, 
treatment within our centre was directed by ABS guidelines 
involving 30Gy in 5 fractions until 2010. From 2010 onwards 
due resource availability an altered schedule of 24Gy in 4 
fractions was implemented. We sought to analyse and 
compare outcomes for these two regimens. 
Materials and Methods: A retrospective analysis of treatment 
and outcomes was conducted for patients receiving primary 
chemo radiation for cervical carcinoma between Nov 2007 – 
Feb 2009 and Feb 2010 - Feb 2011. Overall survival and 
recurrence rates were analysed using Kaplan Meier survival 
analysis. Late toxicity was assessed according to 
RTOG/EORTC Late Morbidity Scoring Scheme. 
Results: 123 patients were identified. Patients received 
pelvic EBRT to a dose of 4500cGy in 25 fractions with a 
combination of platinum based induction or concomitant 
chemotherapy schedules followed by intracavity HDR 
brachytherapy. 59 patients received 3000cGy in 5 fractions 
(Group A) and 64 patients received 2400cGy in 4 fractions 
(Group B) of HDR intracavity brachytherapy. Patient 
characteristics were comparable between Group A and B, 
median age 48 (range 24 – 76) and 50 years (range 30 – 88) 
respectively. Squamous cell carcinoma was the most 
commonly observed histological subtype in both groups. Local 
control rates at 3 years are 75% and 81.6% for Group A and B 
respectively. Distant control at 3 years for Group A is 72.5% 
compared to 84.7% in Group B. There was no significant 
difference in PFS between Groups (log rank p = 0.16). OS at 3 
years in Group A was 58% compared to 73% in Group B (log 
rank p = 0.059). The rate of fistula development was 6.8% 
and 4.7% for Group A and B respectively. Late G3 /4 toxicity 
rates in Group A were reported as 10.2% compared with 
6.25% in Group B.  
Conclusions: A reduced dose fractionation schedule to 
2400cGy in 4 fractions is safely deliverable when compared to 
3000cGy in 5 fractions. There is no increase in recurrence or 
late toxicity seen in our patient group. It may be a preferable 
treatment delivery schedule resulting in reduced theatre 
time, reduced number of insertions and anaesthesia 
requirement.  
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Purpose/Objective: Martinez Universal Perineal Interstitial 
Template (MUPIT) is a device designed for the treatment of 
pelvic malignancies or recurrences via perineal. This 
technique allows treating locally advanced gynecological 
tumors, with a better dose coverage than conventional 
intracavitary therapy. Because of the complexity of this 
technique, it is only performed in experienced centers. There 
are few reports of their use in the literature, and with a little 
number of patients in each study. 
